Key highlights

  • KidneyIntelX.dkd delivered two-year real-world outcome data covering 2,470 patients with type 2 diabetes and early-stage chronic kidney disease.
  • Patients classified as high risk were 10.4 times more likely to experience kidney-function decline than low-risk patients.
  • First-half Revenue was US$1.6 million, while full-year guidance stood at US$4 million.
  • Cash was approximately US$6 million at 31 December 2025, leaving funding and potential dilution as important risks.
  • Renalytix shares have fallen approximately 74% over the past year, leaving the company valued at around £8 million.

AIM-listed diagnostics company Renalytix (LSE:RENX) has delivered some of the strongest clinical validation in its history, yet its shares remain under significant pressure. On 30 June 2026, the group reported two-year real-world outcomes for its FDA-authorised KidneyIntelX.dkd test involving 2,470 patients with type 2 diabetes and early-stage chronic kidney disease. The announcement briefly lifted the shares by approximately 7%, but that rise did little to reverse a sharp decline. Renalytix shares are down roughly 74% over the past year, leaving the company valued at approximately £8 million. The weakness reflects slow commercial adoption, continued losses and limited cash reserves rather than a single recent catalyst. The company’s clinical credibility has yet to translate into commercial scale.

What happened?

The most important recent development at Renalytix was clinical rather than commercial. On 30 June 2026, the company reported significant two-year real-world outcome data for KidneyIntelX.dkd, its FDA-authorised blood test for assessing the risk of disease progression in patients with type 2 diabetes and early-stage chronic kidney disease. The shares rose approximately 7.3% following the announcement.

The broader picture, however, remains one of persistent weakness. Renalytix shares have fallen roughly 74% over the past year and are trading near multiyear lows, giving the company a Market Capitalisation of approximately £8 million. The positive clinical results have not been sufficient to reverse that decline.

The most recent significant financial setback came on 11 February 2026, when a first-half trading update showed revenue of only US$1.6 million. The shares subsequently fell 25% to approximately 4.25p. Management attributed the slower-than-expected commercial progress partly to the time required to integrate test ordering into large health systems’ electronic medical-record systems.

There is no clearly identifiable single catalyst behind the continued weakness. Instead, investors appear to be weighing compelling clinical evidence against slow revenue growth, persistent losses and limited cash reserves.

This disconnect defines the Renalytix Investment case. The company has an FDA-authorised test supported by Medicare reimbursement and substantial clinical evidence, but the market remains concerned that its cash resources could become constrained before commercial adoption reaches scale.

The numbers investors need to know

The clinical findings were significant. The two-year study covered 2,470 patients with type 2 diabetes and early-stage chronic kidney disease across Mount Sinai in New York and Wake Forest and Atrium Health in North Carolina.

Patients classified by KidneyIntelX.dkd as high risk were 10.4 times more likely to experience kidney-function decline than those classified as low risk.

The data also indicated changes in patient management. Approximately 29% of patients who were retested moved into lower-risk categories. Use of SGLT2 inhibitors reached 56% across the study population and 70% at Mount Sinai, while combined use of SGLT2 and GLP-1 therapies increased from 12% to 32%. High-risk patients experienced a reported 43% improvement in the rate of kidney-function decline.

The commercial figures present a less encouraging picture. First-half revenue was US$1.6 million, while full-year guidance stood at US$4 million, compared with US$3 million in the previous year. Cash was approximately US$6 million at 31 December 2025, while the trailing net loss was close to US$15 million.

KidneyIntelX.dkd has FDA authorisation and Medicare coverage at US$950 per test. More than 15,000 patients have been tested cumulatively, but the company has yet to convert that clinical and regulatory progress into revenue at sufficient scale.

Why the market may be concerned

The main concern is the gap between clinical validation and commercial performance. Even strong outcome data have not translated into rapid sales growth, and first-half revenue of US$1.6 million leaves the Business operating at a small scale.

Funding is the most immediate risk. Renalytix held approximately US$6 million of cash at the end of December 2025 while continuing to report substantial losses. Although an accounting loss is not the same as cash burn, the figures indicate that the company may require additional funding unless revenue accelerates or costs fall materially.

A further Equity raise could dilute existing shareholders, particularly given the company’s market capitalisation of only about £8 million. Alternatively, Renalytix may need to secure a licensing agreement, distribution Partnership or strategic investment to strengthen its balance sheet.

Commercial adoption also faces structural obstacles. Management has cited the complexity of integrating KidneyIntelX.dkd ordering into the electronic medical-record systems of major healthcare providers. These integrations can be slow and resource-intensive, delaying revenue even after clinical and reimbursement milestones have been achieved.

The approximately 74% decline in the share price over the past year suggests that investors have lost patience with the speed of commercial adoption, despite the strength of the clinical evidence.

Why bulls may see an opportunity

The bullish case rests on the widening gap between Renalytix’s valuation and the clinical validation of its principal product. The two-year data support the test’s ability to identify patients at greater risk of kidney-function decline and to inform earlier treatment decisions.

The clinical rationale is persuasive. If a reimbursed blood test can identify high-risk patients and encourage wider use of proven therapies such as SGLT2 inhibitors and GLP-1 receptor agonists, it could help delay disease progression and reduce the substantial costs associated with advanced kidney disease.

Important regulatory and reimbursement hurdles have already been cleared. KidneyIntelX.dkd has FDA authorisation and Medicare coverage at US$950 per test. The remaining challenge is therefore primarily commercial: embedding the test into clinical workflows and generating consistent ordering volumes.

Collaborations could help accelerate adoption. Renalytix has worked with Tempus AI on electronic medical-record-integrated testing and with Carna Health on linking population screening to precision intervention.

At an approximately £8 million valuation, any meaningful improvement in test volumes, revenue or strategic funding could have an outsized effect on the shares. The same low valuation, however, also reflects the company’s substantial execution and financing risks.

What happens next?

Funding is the pivotal near-term issue. Investors will watch for a capital raise, strategic investment, licensing agreement or distribution partnership. Each could strengthen the balance sheet, although an equity issue could materially dilute existing shareholders.

Commercial progress will be equally important. Delivery against the US$4 million full-year revenue target, new electronic medical-record integrations and progress with large health-system programmes would provide evidence that the clinical validation is beginning to translate into sales.

The two-year outcome data could also support discussions with healthcare providers, insurers and clinical-guideline bodies. Inclusion in formal treatment guidelines would represent a meaningful commercial catalyst by encouraging wider physician adoption.

With the company’s financial year ending on 30 June, forthcoming full-year results and trading updates will be scrutinised for evidence of accelerating revenue, lower costs and an improved cash runway.

A strategic partnership may offer a faster route to commercial scale than relying solely on organic growth. A licensing or distribution agreement with a larger diagnostics, healthcare or pharmaceutical company could provide both funding and commercial validation.

Outlook

Renalytix (LSE:RENX) illustrates the distance that can exist between clinical credibility and commercial success. Its two-year real-world KidneyIntelX.dkd data were encouraging, showing that high-risk patients were 10.4 times more likely to experience kidney-function decline than low-risk patients. The study also indicated increased use of established therapies and improved outcomes among high-risk patients.

Nevertheless, the shares remain approximately 74% lower over the past year, leaving the company valued at around £8 million. First-half revenue of only US$1.6 million, continued losses and cash of approximately US$6 million explain why the market remains cautious.

There is no single new catalyst behind the ongoing weakness. Instead, the shares are being affected by slow commercial adoption, limited financial resources and the possibility of further dilution.

Bulls may regard the company as a deeply undervalued opportunity based on a clinically validated, FDA-authorised and Medicare-covered test. Bears may see a loss-making micro-cap that must secure additional funding before it can reach commercial scale. Execution and financing—not further clinical validation—are now the decisive issues.